Cancer is a complex disease involving several important changes in cell morphology that ultimately lead to tumor formulation. The biological endpoint of cancer is the uncontrolled growth and proliferation of cells. Resveratrol (RES) is a polyphenolic compound from the stilbene family, which has an important place in the treatment of cancer, which is used as a pharmaceutical and nutraceutical. Studies have shown that RES has anti-tumor effects in addition to its antioxidant, antimicrobial and anti-inflammatory effects. RES protects the body against free radicals and inhibits metabolic events that induce the proliferation of cancer cells. RES is a chemically unstable compound that has problems crossing the blood-brain barrier. Therefore, it is concluded that carrier systems containing RES should be developed in order to increase the water dispersibility of resveratrol and to increase its bioavailability when taken orally. In this way, the RES will be successfully targeted to the tumor site and the undesirable properties of the unstable, heat-sensitive RES will be improved. For this purpose, drug delivery systems prepared using synthetic polymers such as Polylactic-coglycolic acid (PLGA) have been developed. PLGA is a biodegradable and biocompatible polymer used in areas related to human health. In this study, cell culture study of C6 glioma cells obtained from ATCC was performed and for this purpose, biocompatible nanoparticles of RES with PLGA were prepared. With the preparation of these nanoparticles, the effects of RES on cell viability and the differences in the anticancer effect on cells were evaluated with the XTT cytotoxicity study.